APHRIA INC COM NPV (OTCMKTS:APHQF) has continued a steady climb upward. APHQF is at all-time highs and traders have seemingly rewarded this Ontario company for its potential, solid balance sheet and their expansion strategy. Around the Thanksgiving holiday, APHQF received its dealer license and this has cemented a milestone year for the company.
“There is an incredible appetite for high-quality medical cannabis in legal markets around the world. Obtaining our Dealer’s License is a significant milestone in our international expansion strategy as it enables Aphria to have greater control over importing and exporting medical cannabis oil globally,” said Vic Neufeld, CEO of Aphria. “This license will accelerate our speed to international markets and broaden our patient base internationaly, resulting in greater revenue for Aphria.”
APHRIA INC COM NPV (OTCMKTS:APHQF) promulgates itself as a company that produces, supplies, and sells medical cannabis in Canada. Its cannabis products include dried flowers and cannabis oils. APHQF sells its products through its online store and telephone orders, as well as MMPR licensed producers.
According to press materials, “APHQF is one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. APHQF is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licensed producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters.”
Find out when $APHQF reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As the CEO stated above, APHQF is leaning towards the medical-side of the cannabis boom. According to the company, APHQF is well positioned to meet the increasing international demand for medical cannabis in legal markets like Australia, Italy, Germany and Argentina. Aphria is rapidly completing its four-part expansion of its fully-funded facility in Leamington, Ontario, which will increase the greenhouse growing footprint to one million square feet and increase our capacity to supply more than 100,000 kgs of high-quality cannabis at one of the lowest costs in the industry.
One aspect of the company’s plan involved MedLab. Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. With the company growing its patent portfolio, cannabis-based drugs have become a significant part of their research and development. They are currently Medlab at the human trial to test management of intractable pain in oncology patients. The partnership is a majorly progressive step for APHQF because the drug, NanaBis, which could be a major solution upon approval by the licensing body will also be a significant revenue generator for the company long into the future.
“The first shipment of medical cannabis to Medlab is part of our global expansion strategy to take the Aphria story to other regulated countries like Australia and create additional revenue streams,” added CEO Neufeld. “We are proud to be a part of this important research, and we look forward to continuing to provide high-quality, safe and pure medical cannabis products to support Medlab’s clinical research and help patients effectively manage their pain.”
In a previous release, “As Aphria’s first international partner, Medlab shares our vision to advance the use of medical cannabis as an alternative treatment for patients in need. We are proud to be a part of this important research, and we look forward to continuing to provide high-quality, safe and pure medical cannabis products to support Medlab’s clinical research,” said Neufeld.
Earning a current market cap value of $1.33B, APHQF is pulling in trailing 12-month revenues of $22.2M. APHQF is far along in the cannabis sector and represents real value. Many other stocks are hypothetical in this space and pre-revenue. Obviously, that is not the case here and we will be offering updates as more information becomes available. Furthermore, if the NanaBis drug shows progress than shareholders will be in the high life for real. Sign-up for continuing coverage on shares of $APHQF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $APHQF, either long or short, and we have not been compensated for this article.
